
Hutchmed (HCM) announced that following the contract renewal with the China National Healthcare Security Administration, or NHSA, the updated National Reimbursement Drug List, or NRDL, effective on January 1, 2027
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| HCM | HUTCHMED | 14.40 | -0.26 | -1.77% |
| Name | Price | % Change | |
|---|---|---|---|
| $14.40 | -1.77% |

Hutchmed (HCM) announced that following the contract renewal with the China National Healthcare Security Administration, or NHSA, the updated National Reimbursement Drug List, or NRDL, effective on January 1, 2027

Hutchmed (HCM) announced hat the US Food and Drug Administration has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia. Sovleplenib is a novel, selective, oral

Hutchmed (HCM) announces that regulatory filings for Orpathys in combination with Tagrisso have been accepted for review in Europe and Japan. In Europe, the European Medicines Agency, EMA, has validated

Hutchmed (HCM) announced results from the SANOVO Phase III trial in China. Orpathys plus Tagrisso demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint progression-free survival

Hutchmed (China) Limited ($HCM) announced an update on their ongoing clinical study. Hutchmed’s FRUSICA-2 trial, officially titled “A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib

Hutchmed (China) Limited ($HCM) announced an update on their ongoing clinical study. Hutchmed moves early-stage cancer pipeline forward with a first-in-human study of HMPL-A830 in solid tumors. The trial aims

Hutchmed (HCM) “announces that AstraZeneca (AZN) has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS (savolitinib) plus TAGRISSO(R) (osimertinib) for the treatment of patients

Hutchmed (HCM) announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. The first patient

Hutchmed (China) Limited ($HCM) announced an update on their ongoing clinical study. The Phase II study “A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of

BofA raised the firm’s price target on Hutchmed (HCM) to $18 from $16 and keeps a Buy rating on the shares. Despite falling off all-time highs over the past month,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $2.57B | $0.20 | $300.40M | 0.00 | 159.01 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.